AU2020233456A1 - Method for preparing influenza HA split vaccine - Google Patents

Method for preparing influenza HA split vaccine Download PDF

Info

Publication number
AU2020233456A1
AU2020233456A1 AU2020233456A AU2020233456A AU2020233456A1 AU 2020233456 A1 AU2020233456 A1 AU 2020233456A1 AU 2020233456 A AU2020233456 A AU 2020233456A AU 2020233456 A AU2020233456 A AU 2020233456A AU 2020233456 A1 AU2020233456 A1 AU 2020233456A1
Authority
AU
Australia
Prior art keywords
influenza
split vaccine
vaccine
split
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020233456A
Other languages
English (en)
Inventor
Yu Adachi
Manabu ATO
Yoshimasa Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, National Institute of Infectious Diseases, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2020233456A1 publication Critical patent/AU2020233456A1/en
Assigned to JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Sumitomo Pharma Co., Ltd. reassignment JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES Amend patent request/document other than specification (104) Assignors: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, SUMITOMO DAINIPPON PHARMA CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2020233456A 2019-03-04 2020-03-03 Method for preparing influenza HA split vaccine Pending AU2020233456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-038662 2019-03-04
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
AU2020233456A1 true AU2020233456A1 (en) 2021-10-07

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020233456A Pending AU2020233456A1 (en) 2019-03-04 2020-03-03 Method for preparing influenza HA split vaccine

Country Status (14)

Country Link
US (1) US20220152191A1 (en, 2012)
EP (1) EP3936147A4 (en, 2012)
JP (1) JP7545955B2 (en, 2012)
KR (1) KR20210135261A (en, 2012)
CN (1) CN114096273A (en, 2012)
AU (1) AU2020233456A1 (en, 2012)
BR (1) BR112021017310A8 (en, 2012)
CA (1) CA3132578A1 (en, 2012)
EA (1) EA202192398A1 (en, 2012)
IL (1) IL285984A (en, 2012)
MX (1) MX2021010685A (en, 2012)
PH (1) PH12021552094A1 (en, 2012)
SG (1) SG11202109566XA (en, 2012)
WO (1) WO2020179797A1 (en, 2012)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021550175A1 (en) 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法
WO2024225404A1 (ja) * 2023-04-26 2024-10-31 国立感染症研究所長が代表する日本国 抗インフルエンザ抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2744354C (en) * 2008-11-25 2018-10-02 Avir Green Hills Biotechnology Research Development Trade Ag Method for production of ph stable enveloped viruses
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
CN110650729B (zh) * 2017-03-29 2024-08-20 住友制药株式会社 疫苗佐剂制剂
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
PH12021550175A1 (en) * 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
BR112021017074A2 (pt) * 2019-02-28 2021-11-09 Novavax Inc Métodos para prevenir doença ou distúrbio causado(a) por infecção por rsv

Also Published As

Publication number Publication date
BR112021017310A2 (en, 2012) 2021-11-16
IL285984A (en) 2021-10-31
PH12021552094A1 (en) 2022-05-30
EP3936147A4 (en) 2022-09-28
WO2020179797A1 (ja) 2020-09-10
MX2021010685A (es) 2021-12-10
BR112021017310A8 (pt) 2022-12-06
US20220152191A1 (en) 2022-05-19
EA202192398A1 (ru) 2021-11-23
JP7545955B2 (ja) 2024-09-05
EP3936147A1 (en) 2022-01-12
JPWO2020179797A1 (en, 2012) 2020-09-10
CN114096273A (zh) 2022-02-25
SG11202109566XA (en) 2021-10-28
CA3132578A1 (en) 2020-09-10
KR20210135261A (ko) 2021-11-12

Similar Documents

Publication Publication Date Title
US11732031B2 (en) Method for producing influenza HA split vaccine
AU570929B2 (en) Broad spectrum influenza antisera
US4625015A (en) Broad spectrum influenza antisera
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
AU2020233456A1 (en) Method for preparing influenza HA split vaccine
Xuan et al. Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines
JP2023052092A (ja) 免疫原性組成物
US20230406910A1 (en) Method for producing influenza ha split vaccine
WO2009152518A1 (en) Novel peptide adjuvant for influenza vaccination
US8883165B2 (en) Modified peptide vaccine derived from influenza M2
JP6602762B2 (ja) ウイルス様粒子を含むワクチン
TWI857017B (zh) 流感ha裂解疫苗之製造方法
HK40068192A (en) Method for preparing influenza ha split vaccine
CN114106204A (zh) 一种具有多种甲型流感病毒免疫原性的融合蛋白及其制备与应用
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
JP2023515829A (ja) 小児対象のための高用量インフルエンザワクチン
WO2010146848A1 (en) An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES